Acute Coronary Syndrome ; therapy ; Humans

Acute Coronary Syndrome ; epidemiology ; therapy ; Humans

Acute Coronary Syndrome ; therapy ; Angioplasty, Balloon, Coronary ; Humans

Acute Coronary Syndrome ; physiopathology ; therapy ; Electrocardiography ; Humans ; Practice Guidelines as Topic

Acute Coronary Syndrome ; physiopathology ; therapy ; Electrocardiography ; Evidence-Based Medicine ; Humans

Humans ; Acute Coronary Syndrome/therapy* ; Platelet Aggregation Inhibitors ; Risk Assessment

Humans ; Acute Coronary Syndrome/therapy* ; Platelet Aggregation Inhibitors ; Risk Assessment

Vulnerable plaque rupture is the main cause of acute coronary syndrome (ACS), a representative cardiovascular thrombotic disease. Considering that the Western medical pathogenetic recognition on vulnerable plaque inflammatory reaction and thrombus formation is similar to the etiopathogenesis and clinical characteristics of toxin and stasis as well as the clinical manifestation of toxic-stasis in TCM, the authors believe that it is necessary to expand the previous TCM thinking on taking blood stasis as the main etiopathogenesis for ACS to that ACS is caused by the toxic-stasis induced vulnerable plaque rupture. Therefore to make sense, depending evidence-based medical principle, the relationship between toxic-stasis and vulnerable plaque forming and rupturing, and to form the clinical norm for diagnosis and treatment of toxic-stasis should be helpful for the prevention and control of ACS.
Acute Coronary Syndrome ; diagnosis ; pathology ; therapy ; Coronary Thrombosis ; diagnosis ; pathology ; therapy ; Humans

Acute Coronary Syndrome ; therapy ; Angioplasty, Balloon, Coronary ; Humans ; No-Reflow Phenomenon ; prevention & control

BACKGROUND AND OBJECTIVES: Recent randomized studies have shown a significant reduction in the rate of recurrent cardiac events with adjunctive pharmacotherapy, using Glycoprotein IIb/IIIa inhibitors (GPI), in patients undergoing percutaneous coronary intervention (PCI) procedures. However, in Korea, there is a paucity of data concerning complications of tirofiban therapy in patients with acute coronary syndrome (ACS). Therefore, this study was performed to evaluate the safety of tirofiban therapy. SUBJECTS AND METHODS: ACS patients who underwent tirofiban administration between May 2002 and October 2003 were reviewed. The rates of bleeding, transfusion, and thrombocytopenia were analyzed, and the rates of complications by ages, gender and PCI compared with medical treatment, renal function and vascular access route. RESULTS: A total of 261 ACS patients (male/female=150/111) underwent tirofiban therapy. The mean ages of the subjects was 64.5 years, the rates of minor bleeding, major bleeding, transfusion and thrombocytopenia were 8.1% (n=21), 2.3% (n=6), 4.6% (n=12) and 1.2% (n=3), respectively. Minor bleeding occurred at similar rates in both sexes (8 vs. 8.1%) and to a greater extent in old age (> or =65) (12.5 vs. 2.6%, p=0.093), but major bleeding occurred to a greater extent in females and old age (5.4 vs. 0% and 4.2 vs. 0%, p=0.25 and 0.093, respectively). The rates of thrombocytopenia and transfusion were greater in old age (2.1 vs. 0% and 8.3 vs. 0%, p=0.052 and 0.087, respectively). In-hospital days were greater in old age (14.7+/-9.5 vs. 11.9+/-4.4 days, p=0.065). The rates of complications were similar in both groups when compared by PCI or medical treatment and vascular access route. The serum creatinine was 3.3 mg/dL in those with major bleeding, which was higher than in the other groups (p=0.000). CONCLUSION: The tirofiban therapy in patients with ACS did not induce an increase in the bleeding rates, in-hospital days and it was safe and well tolerated in old age.
Acute Coronary Syndrome* ; Coronary Disease ; Creatinine ; Drug Therapy ; Female ; Glycoproteins ; Hemorrhage ; Humans ; Korea ; Percutaneous Coronary Intervention ; Thrombocytopenia